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Abstract 
The immune responses in the mouse brain to intracranially and intradermally transplanted 
mouse l戸nphomaswere compared by means of an appropriate design of a genetic distance be-
tween host and tumor. Antilymphoma graft resistance in the brain was clear not only in the 
allogeneic combinations, but also in those of the semisyngeneic host and challenging tumor. 
Enhanced resistance against the second intracranial tumor injection was also observed in al 
combinations of host mice and tumors. Furthermore, after rejection of the tumors whether 
implanted intradermally or intracranially, the allogeneic cytotoxic responses were induced to 
the same extent in the spleens using an in vitro cell-mediated cytotoxicity assay. Using athymic 
nude mice as recipients, the transplantation resistance detected in the brain was suggested to 
depend on T-cell mediated immunological responses. 
In conclusion, we propose that the brain is not an“immunological privileged" site. The 
resistance to lymphoma graft in the brain is mediated by T-cells and is dependent on immuno-
logical responses which are essentially the same as those seen in peripheral sites. 
Introduction 
Several reports have been published concerning the transplantation immunity in the brain. 
In the 1920s, both SHIRAr27) and MuRPHY19) demonstrated that tumors transplanted to the 
brain would often grow, although the same tumors transplanted subcutaneously were rejected. 
These observations were extended by MED AW AR 1へwhoshowed that histoincompatible skin graft, 
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that underwent rapid rejection when transplanted subcutaneously, would grow indefinitely when 
transplanted to the brain, but distant from the ventricular system. Since Medawar’s description 
of the brain as an "immunologically privileged”site、conflictingreports have been made on the 
ability of the brain to support the growth of transplanted allografts of normal and neoplastic 
tissues for prolonged periods. GREEN9-11> studied the transplantation of heterologous tissues 
to the brain, and found that metastatic human cancer, as well as human glioblastomas and 
medulloblastomas, can grow in the brains of laboratory animals11>. However, there has been 
a need for additional critical studies using inbred strains as hosts in order to define the limitation 
of the brain as a so-called privileged site. ScttEINBERG et al.24-26> published analytical studies 
using a mouse epend戸noblastomaand various inbred strains of mice as hosts. They reported 
that the intracerebral tumor isotransplants grew progressively with a negligible lymphocytic 
response in the brain, whereas intracerebral isotransplants to specifically immunized mice were 
associated with a massive lymphocytic infiltration of the tumor periphery with necrosis of tumor 
cels. 
Successful intracerebral sensitization against mouse gliomas was also shown by SCHEINBERG 
et al.2&>. In these experiments, gliomas were transplanted to the brains of isologous mice and 
cured by irradiation. Subsequent tumor isotransplants to the skin or brain were rejected in 
significant numbers when compared to unexposed hosts. However, MEDAWAR17> had previously 
shown that, although skin homografts transplanted to the brain of unsensitized animals could 
survive indefinitely, such a graft placed in the brain of a sensitized animal underwent rapid 
destruction mainly by lymphocytes, which also accumulated in the surrounding brain. Ac-
cording to these observations, ScHEINBERG et al.25•27> concluded that“immunological privilege" 
was far from complete and that an initial exposure to a tumor transplant within the brain could 
provide some degree of immunity to a subsequent subcutaneous or intracerebral injection. 
Recently, other reports have shown that primary sensitization can take place in rats grafted with 
allogeneic skin in the brain8・2>. These studies have also shown the occurrence of primary 
allograft reactions directed against tumor associated histocompatibility antigens7• 21>. 
In this paper, we demonstrate the presence of host resistance against intracerebral lymphoma 
graft not only against tumor-associated histocompatibility antigens in allogeneic models, but 
also against tumor-associated transplantation antigens in histocompatible recipients. The cel-
mediated immune responses to the tumor graft in the brain were not essentially different from 
those seen in other tissues. 
Materials and Methods 
Mice: We used male and female mice between 6 and 10 weeks of age. These were highly 
inbred BALB/c, C57BL/6, DBA/2 strains and their hybrids, (BALB/c×C57BL/6)F i (CB6F i*) 
and (C57BL/6×DBA/2)F i (B6D2F i). These mice were maintained in the Facilities of Ex-
perimental Animals, Faculty of Medicine, Kyoto University. We also used male and female 
BALB/c-and CB6F1-nu/nu mice, maintained under pathogen free conditions and between 8 
and 14 weeks of age. 
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Tumors: RL舌1(kindly provided by Dr. E. NAKAYAMA, The Center of Adult Disease, 
Osaka, Japan), is a radiation-induced leukemia of BALB/c origin. Other tumors used in the 
p閃sentstudy were P815 (a methylcholanthrene-i吋 l悶 dmastocytoma of DBA/2 origin) and 
EL-4 (a dimethylbezanthrec沼田ーinducedleukemia of C57BL/6 origin). All tumor cells had been 
maintained in our laboratory, in syngeneic strains in ascitic form. 
Transplantation of Tumor: Tumor cells were harvested, washed three times and 
resuspended at the desired concentrations in Hanks’balanced salt solution (HESS). For 
intradermal (ID) injection, tumor目 lsin a volume of 0.1 ml were inj配 tedon the back of the 
mice with 1 ml disposable tuberculin syringe and a 26-gauge needle, and for intracranial (IC) 
i吋ectiontumor cells in a volume of 0.01 ml were injected under sterile conditions through the 
right cranial bone to 2 mm in depth with the aid of a 0.05 ml glass microsyringe (Hamilton Co・3
Reno, NA.) and a 27-gauge Y AOI needle13>. In the mice of tumor rejection, the ID tumor grew 
to 5-10 mm in diameter in 2 weeks, and then regressed within 3-4 weeks as reported by ours in 
CB6F1 mice injected with RL古1cellsl4,1s人 Themacroscopical disappearance of the ID tumor, 
and survival of the mouse for more than 60 days after the IC injection of tumors was consid-
釘edto be a tumor rejection. 
Preparation of Spleen Cells: The spleen cells of C57BL/6 mi白 whichhad been同ected
with l×105 RL 6 1 cells intracranially or intradermally were aseptically removed at indicated 
time points after injection. Then, the spleen cells were crushed gently on a stainless steel 
mesh in HBSS. After removing large cell clumps and debris by passing through cotton wool, 
the spleen cells were centrifuged, washed thr巴巴 times and then resuspend巴din RPMI-1640 
(Grand Island Biological Co.，印刷 Island,NY) supplemented with 10% fetal calf serum 
(FCS) (Flow Laboratories, Inc., Rockville, MD) in order to perfoロncell-mediated cytotoxicity 
assay. 
Cell-mediated Cytoxicity Assay: Target cels were labeled with 51Cr by incubating 5 X 
106 cels with 0.1 mCi of Na2Cr04 (Japan Atomic Research Institute, Tokyo, Japan) in 0.1 ml 
RPMI・1640with 10% FCS. Effector cells (2×10s) were mixed with l×104 s1cr-labeled target 
cels in a total 0.2 ml in the wells of a V-bottorned microculture plate (Limbro Scientific, Ham-
den, CT). After centrifugation at 200×g for 1 min., the cultures were incubated at 37°C 
for 5 hrs in a humidified atmosphere of 5% C02 in air. Following incubation, the plate was 
centrifuged at 200×g for 5 min. and 0.1 ml of supernatant was removed and assayed for radio-
activity. Spontaneous release was determined by incubating 51Cr-labeled target cells alone, and 
total labeling was determined by counting the radioactivity of l×104 target cells directly. 
The following formula was used to compute percent cytolysis: 
Test cpm-Spontaneous pm 
よとこ×100(%) 
Total cpm-Spontaneous cpm 
Results 
Primary Graft Resistance: Table 1 shows the genotypical relationship between host 
mice and tumors used in the present study. The relationship between host mice and tumors 
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Teble 1. Genotypical relationship between host mice and tumors. 
H-2 Tumors 
Host mice 
haplotype RL合l P815 EL-4 
BALB/c d MAHC•> MIHICb> MAH IC<> 
DBA/2 d MIHIC MAHC MAHIC 
C57BL/6 b MAHIC MAHIC MAHC 
CB6F1d> d/b MAHC MIHIC MAHC 
B6D2F1•> b/d MIHIC MAHC MAHC 
•> M勾orhistocompatible 
切 Minorhistoincompatible 
c) Major histoincompatible 
d> (BALB/c×C57BL/6)F1 
•> (C57BL/6×DBA/2)F1 
was classified into three categories: 1) major histocompatible (syngeneic), 2) major histocom-
patible but minor histoincompatible and 3) major histoincompatible (allogeneic). The proper 
expression of mouse major histocompatibility antigens (H-2) on each tumor cells was confirmed 
by a complement-dependent cytotoxicity test using an appropriate anti-H-2 alloantiserum (data 
not shown). As shown in Table 2, tumor rejection was not seen in either ID nor in IC injection 
in the syngeneic combination of host and tumor. When BALB/c mice were i吋ectedwith 
1×105 RL苫1cells either intradermaly or intracranially, mean survival time was 25.5 days and 
13.2 days, respectively. The mice injected with tumor cells intracranially began to lose weight 
on about day 10. Extracranial invasion of the intracranially-transplanted tumors was not noted. 
In a semisyngeneic combination, as seen in the lower half of Table 2, some mice, especially 
CB6F i mice injected with RL舌1,survived after ID injection, on the other hand no mice survived 
Teble 2. Lymphoma graft response against major histocompatible host. 
Tumors Site 
Doses of tumor cels i吋ected
Host 
5×104 1×105 5xl05 1×106 
BALB/c RL61 ID•> 0/8b) 0/9 0/8 0/9 
IO叫 0/9 0/10 0/12 NTd> 
DBA/2 P815 ID NT 0/9 0/1 0/7 
IC 0/9 0/10 0/9 NT 
C57BL/6 EL-4 ID 0/6 0/9 0/8 NT 
IC 0/7 0/9 0/10 NT 
CB6F1 RL61 ID 8/8 7/7 8/8 6/9 
IC 0/8 0/9 0/8 NT 
CB6F1 RL古1 ID NT 0/5 0/6 0/5 
-nu/nu IC 0/5 0/5 NT NT 
B6D2F1 P815 ID 3/6 2/7 0/8 NT 
IC 0/7 0/8 0/9 NT 
的 Intradermalinjecti 
b) Number of mice, rejected/tested 
c) Intracranial injection 
dJ Not tested 
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Teble 3. Lymphoma graft response against minor histoincompatible host. 
Host Tumor Site 
Doses of tumor cels i吋ected
5×104 1×1Q5 5×1Q5 1×lQ6 
BALB/c P815 ID NT•> 6/6b) 7/7 NT 
IC 2/5 3/9 1/8 NT 
DBA/2 RL古1 ID 5/5 6/6 3/6 NT 
IC 3/6 5/8 0/7 NT 
CB6F1 P815 ID 4/4 5/5 6/6 4/8 
IC 3/5 4/6 3/6 NT 
CB6F1 P815 ID NT 0/5 0/5 NT 
-nu/nu IC 0/5 0/5 NT NT 
B6D2F1 RL古1 ID 5/5 5/5 4/4 NT 
IC 4/6 4/7 2/6 NT 
•> Not tested 
b) Number of mice, rejected/tested 
after IC injection. CB6F 1anti-RL6 1 effector cells are known to recognize a unique cell surface 
antigen on leukemia RL古1cells20>. Therefore, the present results suggest that a primary 
immune response strong enough to reject the tumors could not ne detected in the brain in the 
present experimental protocol. Table 3 shows the graft resistance against minor histoincom-
patible l戸nphomacells. Although al the mice injected with less than l×1Q5 tumor cells intra-
derrnally rejected the tumors, the rejection after the IC injection was not complete as seen in ID 
site. All the CB6F1-nu/nu mice injected with P815 tumor cells in both sites died. These results 
indicate that the immunological response against the minor histocompatibility antigens expressed 
on the grafted tumors was demonstrated in the brain as well as in the peripheral tissue. How司
ever, clearly fewer mice rejected the IC tumors than the ID tumors in the tumor dose range 
examined in this experiment. This suggests that the course of tumor rejection in the brain may 
be different from that the ID tumor. The majority of the mice that received IC or ID i吋ection
of major histoincompatible tumors with less than 1×105 cells survived as shown in Table 4. 
Teble 4. Lymphoma graft response against major histoincompatible host. 
Doses of tumor cels inoculated 
Host Tumor Site 5×104 1×lQ5 5×lQ5 1×106 
BALB/c EL-4 ID 7/7叫 7/7 8/8 6/8 
IC 5/5 5/6 2/7 0/6 
BALB/c EL-4 ID NT 0/4 NT NT 
“n昨1 IC 0/4 NT NT NT 
DBA/2 EL-4 ID 5/5 5/7 3/8 1/8 
IC 3/6 2/7 1/6 0/8 
C57BL/6 RL古l ID 7/7 8/8 9/9 8/8 
IC 9/9 10/10 9/9 4/8 
C57BL/6 P815 ID 6/6 8/8 7/7 8/8 
IC 6/6 9/9 10/10 719 
•> Np:mber of mice, rejected/tested 
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Teble 5. Secondary intracerebral antilymphoma graft response. 









b) Primary response 
吋 Minorhistoincompatible 




MAHI Cd> 8/8(5/6) 
MAHIC 3/9(2/7) 
Fewer mice survived the IC injection of more than 5×10s cells than the mice with ID twnor 
cells as seen in minor histoincompatible combination. In this experiment and the next, in which 
EL-4 tumor cells were injected at the IC or ID site, the frequency of rejection was low both in 
BALB/c and DBA/2 mice. Generally, with EL-4, the mean survival time was shorter than that 
of other tu立iors. These findings suggest that the characteristics of EL-4 cells to grow rapidly 
after injection both in IC and ID sites (data not shown). Furthermore, the results that both 
CB6F i-nu/nu and BALB/c・nu/numice injected with allogeneic tumors (Table 3 and 4) failed to 
reject the tumor indicated the importance of T-cell mediated immunocompetence both in IC 
and ID sites. 
Secondary IC Graft Resistance: Next experiments were designed to assess whether the 
host extracranial presensitization would confer an enhanced transplantation resistance in the 
brain that could be measured by survival criteria. The mice that survived after ID injection of 
Teble 6. No different cytotoxic activi句rwas seen between intradermal 
and intracranial injection of MAHIC lymphoma graft. 
Time•> (week) % Lysisb> 
ID IC 
1 10. 6±3. 3 8-4土3.7c> 
(35-6土6-5 28-3土4-8)d> 
2 40. 3±6. 4 34.6土6-3
(24-3士4-2 20.5土3.9) 
3 34-3土5.7 33.1±5. 9 
( 6.5土3-1 5.8土2-1)
4 32-6土5,5 25.2土5-6
叫 Timeafter injection of RL古1(1x105) in C57BL/6 mice. 
b) Cytotoxic activity of spleen cels by 5・hrs1cr release assay, 
efector to target ratio 50 : 1.
c) Target cel: RL古1. The differences of % lysis between ID and 
IC groups were not significant. 
d) Target cel: Y AC・1. The difference of % lysis between ID and 
IC groups were not significant (p>0.05). 
TRANSPLANTATION IMMUNITY 197 
l×10s cels were used as recipients of IC tumor injection 4 weeks after ID injection (Table 5). 
In the semisyngeneic combination, al presensitized CB6F i mice survived after IC injection (8/8). 
In contrast, none survived after the primary injection (0/8). Enhanced resistance against the 
second IC tumor injection was also observed in most of the combinations other than DBA/2 and 
EL-4. 
Comparison of Cytotoxic Activity Induced in Spleens: Primary in vitro cytotoxic 
activities induced in spleens of tumor-rejected mice were compared between the two groups. As 
shown in Table 6, the peak of cytotoxic activity against RL古1cells was observed 2 weeks after 
the injection of RL古1in C57BL/6 mice in both ID and IC sites (40.3土6.4%and 34.6土6.3%).
The peak of cytotoxic activity in the spleen coincided with the maximum size of the ID tumor. 
The ID tumor regressed thereafter, and disappeared macroscopically by day 30. No significant 
difere町 ein cytotoxic activity was seen between ID and IC injection. These results indicate 
that both routes of injection with allogeneic tumors can induce killer cels to the same degree. 
Discussion 
The central nervous system (CNS) has been thought to be an“immunologically privileged 
site" because of its inability to develop allograft or even xenograft reactions9, 17, 19). Recent 
observations, however, suggest that immunological responses to intracranial tumors can be 
built2·5·1丸山 18•29>. Primary sensitization has been reported to occur in rats bearing allogeneic 
skin in the brain22>, and recently an occurrence of primary allograft reactions directed against 
tumor-associated histocompatibility antigens of lymphoma grafts was also demonstrated7•21>. 
ALBRIGHT et al.1> showed that gliosarcoma 9L in inbred rats exhibited parallel growth in 
subcutaneous and intracerebral sites, suggesting that the genetic control of tumor growth was the 
same whether in the brain or subcutaneously. The growth of a tumor on the brain is also subject 
to the establishment of tolerance12>. This was studied by an experiment in which Lewis rat 
sarcoma cels were injected into the brain of rats of the A VN strain. If the recipients were first 
rendered tolerant to the donor strain by neonatal injection of bone marrow cels, gra丘survivalwas 
greatly enhanced 12> 
In the present study, primary allogeneic and semisyngeneic resistance were clearly observed 
using lymphoma cells and various ho&t combinations. Allogeneic resistance in the C:¥'S seemed 
easier than semisyngeneic resistance as judged by survival criteria (Table 2, 3, 4). In the allo-
geneic combination of hosts and tumors, the resistance seen in the major histoincompatible 
combinations was more evident than that seen in the minor histoincompatible combinations 
(Table 3, 4). These results were grossly consistent with those obtained in ID sites. The di百eren
genetic distances of host and tumor combinations might be explained by the di釘erentantigens 
expressed on l戸nphomagrafts. 
The immunological responses in the CNS may be due to the presence of the blood brain 
barrier (BBB). The BBB is interposed between the blood vessels and the CNS, regulating the 
entry of substances into the brain. SHUTTLEWORTH2B> reported that the normal brain capillary 
endothelium lacked the fenestrations seen in other organs, and pointed tight junctions which 
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excluded large proteins from normal brain parech戸na. The BBB was originally seen as a single 
exclusionary interface, but the situation is more complex. According to RAPOPORT23九thereis 
no single barrier but “a series of regulatory interfaces”，which determine the rate at which various 
substances pass into the brain. It is now believed that, whereas an effective BBB exists in the 
normal brain, it is to some extent lost in a diseased brain. It would appear that, when the CNS 
is damaged, for instance, by the development of a tumor, the condition of immunological 
privilege could be substantially lost6> 
Another possible explanation that may also contribute to the BBB is the absence of lymphatic 
drainage in the cerebral parench戸na. The brain and spinal cord are generally considered to 
have no significant l戸nphaticvessels or l戸nphaticdrainage system. There are minor pathways 
in the nasal olfactory lymphatics and peridural lymphatics of the nerve roots, but these are 
probably negligible as a method of 1戸nphaticdrainage from the cerebral p乱renchyma.Therefore, 
the absence of organized lymphoid tissue reflects the fact that the brain is not normally exposed to 
significant levels of antigenic stimulation. It is an inaccessible organ, shielded from attack by 
invading organi釘ns,and relatively impermeable to antigens reaching it from the bloodstream. 
In the present study, primary graft resistance was easily detected in murine brain against 
allogeneic lymphoma cells (Table 4). These resistance appeared relatively "weak”compared to 
that seen in ID sites. However, relatively similar degree of cytotoxic activity was detected in 
spleen cells in allogeneic lymphoma transplanted mice in both IC and ID sites (Table 6). This 
relatively “weak”resistance in the brain means that the number of mice which rejected the 
allogeneic tumor intracranially is significantly lower than that of the mice injected intradermally 
with the same number of tumor cells at both the IC and ID sites (Tables 3, 4). An important 
problem to be discussed is that the procedure to transplant the tumor cells injected IC in a volume 
of 0.01 ml with a 27 gauge needle could cause mechanical destruction of brain parench戸naand 
disruption of the BBB followed by perifocal brain edema. However, our control experiments of 
IC injection of 0.01 ml HBSS alone support to the contrary. Furthermore, temporary growth of 
IC tumor was found by histological examination (data not shown), and PUCCETTI et al.21> found 
similar results to ours with radioisotopic techniques. In both cases, allogeneic tumors were 
completely rejected and the animal survived. In such a case, the mice that received allogeneic 
tumors intracranially would not to be survived because of th巴increasedintracranial pressure due 
to the tumor growth and brain edema, even if an immune response, strong enough to lyse the 
tumors to some extent, was produced. This peculiar phenomenon may affect the results, since the 
intracranial space of mice is very small and limited. In this sense, the experiments using organ 
or skin grafts are essentially different from those using tumor grafts because an organ or skin 
graft would not proliferate as tumor grafts. 
Another problem iswhether the semistereotaxic procedure of the injection of tumor cels 
through the head skin and cranial bone could cause contamination of lymphoid cells from head 
skin or periphery. If it does, the results obtained after IC transplantation might not reflect com司
pletely the reaction occurring in the brain. Direct evidence to solve this problem is lacking now, 
but extracranial invasion of the tumors transplanted intracranially was not seen. If the intra-
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cranial tumors should extend extracranially along the needle path, a systemic immune response 
could occur. 
The primary response against tumor-associated transplantation antigen was investigated in 
histocompatible recipients. In this experiment of CB6F i grafted with RL古1cells which bear 
a unique cel surface antigen20>, no evidence of intracranial resistance was obtained, on th巴
contrary, ID tumors induced by 5×105 cells (Table 2) were completely rejected. ID host sensi-
tization with RL古1resulted in considerable protection against IC injection of the same tumor 
(Table 5). 
CrRCOLO et al. 4> showed that the mouse brain can be considered an“immunologically 
privileged＇’sit巴fornatural resistance more than T-dependent classical graft response. They 
concluded that classical graft resistance was easily detected in the brain of allogeneic nonirradi-
ated recipients, but that only marginal natural resistance could be detected in mouse brain by 
mortality studies in nonirradiated hemopoietic histocompatible hybrid or nude mice. 
CHIU et aJ.s> reported that no significant cell-mediated cytotoxity was s巴enin short t巴ロn
(4 hrs) cytotoxity assays with spleen cells obtained from C-6 glioma-bearing rats at any stage 
of tumor growth, and that the glioma-bearer serum, though not cytotoxic to the C.6 cells alone, 
became cytotoxic with the addition of rabbit complement. In our studies, allogeneic cell 
mediated cytotoxity was detected in the 5-hr 51Cr-release assay from 1 week after the IC injection 
of tumor cels. In our semisyngeneic system, no significant cell-mediated cytotoxity was detected 
usingRL古1tumor cells and CB6F1 mice in the 5 hr 51Cr-r巴leaseassay, but the humoral immune 
response is unknown. 
We believe that th巴brainshould no longer be called an“immunologically privileged" site, 
and that our findings could be helpful in explaining the effectiveness of systemic adoptive im-
munotherapy to the brain tumors. 
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和文抄録
マウス脳内における免疫応答
1. マウスリンパ腫に対する移植免疫
京都大学医学部脳神経外科
樺 篤ヘ半田 肇，山下純宏
同 免疫研究施設
栗林景容，増田 徹
＊現籍天理よろづ相談所病院脳神経外科
実験腫湯fC対するマウス脳内における免疫応答を皮 内においても半同系，異系閣の移植腫蕩片の拒絶反応
下移植モデルと比較し，脳内免疫応答の特殊性の有無 が認められ，ヌードマウスを用いた実験よりこれら拒
ILっき検討した． 絶反応がT細胞を主体とした免疫応答によりなされて
遺伝的背景の異なる 3種類の純系マウスおよび同マ いるととが観察された．しかし，脳内においては皮下
ウスに誘発された同系腫蕩3種類，又純系マウス間の と異なり移植細胞数によっては，異系聞の腫湯植片拒
第1代雑穫を用い，腫蕩の移植後の拒絶の有無を同系， 絶も完全IL行われない場合があり，免疫応答能lζ差が
半同系，異系の腫蕩ーマウス間の関係、で皮下と脳内で あるものと推察された．
比較観察した．その結果，基本的には皮下と同様に脳
